Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 12Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 7Cholangiocarcinoma 5Biliary Tract Neoplasms 5Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Carcinoma 3Breast Neoplasms 3Respiratory Tract Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Bile Duct Neoplasms 2Unresectable Hepatocellular Carcinoma 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Diseases 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × durvalumab × 30 days × Clear all
NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡